1. Home
  2. BGT vs PHAT Comparison

BGT vs PHAT Comparison

Compare BGT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGT
  • PHAT
  • Stock Information
  • Founded
  • BGT 2004
  • PHAT 2018
  • Country
  • BGT United States
  • PHAT United States
  • Employees
  • BGT N/A
  • PHAT N/A
  • Industry
  • BGT Trusts Except Educational Religious and Charitable
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • BGT Finance
  • PHAT Health Care
  • Exchange
  • BGT Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • BGT 300.3M
  • PHAT 289.0M
  • IPO Year
  • BGT N/A
  • PHAT 2019
  • Fundamental
  • Price
  • BGT $12.09
  • PHAT $3.14
  • Analyst Decision
  • BGT
  • PHAT Strong Buy
  • Analyst Count
  • BGT 0
  • PHAT 5
  • Target Price
  • BGT N/A
  • PHAT $17.80
  • AVG Volume (30 Days)
  • BGT 107.2K
  • PHAT 2.2M
  • Earning Date
  • BGT 01-01-0001
  • PHAT 05-01-2025
  • Dividend Yield
  • BGT 10.77%
  • PHAT N/A
  • EPS Growth
  • BGT N/A
  • PHAT N/A
  • EPS
  • BGT N/A
  • PHAT N/A
  • Revenue
  • BGT N/A
  • PHAT $81,859,000.00
  • Revenue This Year
  • BGT N/A
  • PHAT $201.74
  • Revenue Next Year
  • BGT N/A
  • PHAT $114.16
  • P/E Ratio
  • BGT N/A
  • PHAT N/A
  • Revenue Growth
  • BGT N/A
  • PHAT 3055.70
  • 52 Week Low
  • BGT $10.89
  • PHAT $2.35
  • 52 Week High
  • BGT $13.42
  • PHAT $19.71
  • Technical
  • Relative Strength Index (RSI)
  • BGT 50.64
  • PHAT 40.55
  • Support Level
  • BGT $12.00
  • PHAT $2.21
  • Resistance Level
  • BGT $12.58
  • PHAT $4.45
  • Average True Range (ATR)
  • BGT 0.18
  • PHAT 0.42
  • MACD
  • BGT 0.03
  • PHAT -0.08
  • Stochastic Oscillator
  • BGT 43.68
  • PHAT 41.52

About BGT BlackRock Floating Rate Income Trust

Blackrock Floating Rate Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income. The company's secondary investment objective is to seek the preservation of capital. The Trust seeks to achieve its investment objectives by investing mainly, under normal conditions, at least 80% of its assets in floating and variable rate instruments of U.S. and non-U.S. issuers, including a substantial portion of its assets in floating and variable rate securities including senior secured floating rate loans made to corporate and other business entities.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: